Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives.

Contraception - 1 Jul 2004

Sidney Stephen, Petitti Diana B, Soff Gerald A, Cundiff Deborah L, Tolan Kimberly K, Quesenberry Charles P

Abstract excerpt

OBJECTIVE: To assess the relationship between venous thromboembolic disease (VTE) and use of low-estrogen dose (<50 microg) combined estrogen-progestin oral contraceptives (OC) and three thrombosis-related gene mutations in a United States population. DESIGN: This case-control study was conducted in 1998-2000 among women ages 15-44 years who were members of the Kaiser Permanente Medical Care Program [KPMCP]...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Confidence Intervals
Share to Estrogens

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Factor V

Share to Interviews as Topic

Share to Obesity

Share to Progestins

Share to Prothrombin

Share to Venous Thrombosis

Source

Identifiers

PMID: 15208046
DOI: 10.1016/j.contraception.2004.02.010

Genes

MTHFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives.PMID 15208046Read ↗

HORMONE EXPOSURE AND VENOUS THROMBOEMBOLISM IN COMMERCIALLY-INSURED WOMEN 50 TO 64 YEARS OF AGESemantic proximity Read ↗

Genome-wide investigation of exogenous female hormones, genetic variation, and venous thromboembolism risk.Semantic proximity Read ↗

Risk factors for venous thromboembolism in pre-and postmenopausal women.Semantic proximity Read ↗

Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis.Semantic proximity Read ↗

The joint effect of genetic risk factors and different types of combined oral contraceptives on venous thrombosis risk.Semantic proximity Read ↗

Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception.Semantic proximity Read ↗

The effect of prothrombotic blood abnormalities on risk of deep vein thrombosis in users of hormone replacement therapy: a prospective case-control study.Semantic proximity Read ↗

Risk factors for venous thromboembolism in women under combined oral contraceptive. The PILl Genetic RIsk Monitoring (PILGRIM) Study.Semantic proximity Read ↗

Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration.Semantic proximity Read ↗

Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis.Semantic proximity Read ↗

The epidemiology of venous thromboembolism in Caucasians and African-Americans: the GATE Study.Semantic proximity Read ↗

Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.